Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer
- PMID: 31907632
- DOI: 10.1007/s00345-019-03066-1
Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer
Abstract
Purpose: Whole-body positron emission tomography/magnetic resonance imaging (wbPET/MRI) is a promising diagnostic tool of recurrent prostate cancer (PC), but its role in primary staging of high-risk PC (hrPC) is not well defined. Thus, the aim was to compare the diagnostic accuracy for T-staging of PET-blinded reading (PBR) and PET/MRI.
Methods: In this prospective study, hrPC patients scheduled to radical prostatectomy (RPx) with extended lymphadenectomy (eLND) were staged with wbPET/MRI and either 68Ga-PSMA-11 or 11C-choline including simultaneous multiparametric MRI (mpMRI). Images were assessed in two sessions, first as PBR (mpMRI and wbMRI) and second as wbPET/MRI. Prostate Imaging Reporting and Data System criteria (PIRADS v2) were used for T-staging. Results were correlated with the exact anatomical localization and extension as defined by histopathology. Diagnostic accuracy of cTNM stage according to PBR was compared to pathological pTNM stage as reference standard.
Results: Thirty-four patients underwent wbPET/MRI of 68Ga-PSMA-11 (n = 17) or 11C-choline (n = 17). Twenty-four patients meeting the inclusion criteria of localized disease ± nodal disease based on imaging results underwent RPx and eLND, whereas ten patients were excluded from analysis due to metastatic disease. T-stage was best defined by mpMRI with underestimation of tumor lesion size by PET for both tracers. N-stage yielded a per patient sensitivity/specificity comparable to PBR.
Conclusion: MpMRI is the primary modality for T-staging in hrPC as PET underestimated T-stage in direct comparison to final pathology. In this selected study, cohort MRI shows no inferiority compared to wbPET/MRI considering N-staging.
Keywords: Choline; MRI; PET; PSMA; Prostate cancer.
Similar articles
-
Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology.BJU Int. 2020 Jul;126(1):83-90. doi: 10.1111/bju.14858. BJU Int. 2020. PMID: 31260602
-
Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.Eur Urol Oncol. 2019 Mar;2(2):166-173. doi: 10.1016/j.euo.2018.08.011. Epub 2018 Sep 22. Eur Urol Oncol. 2019. PMID: 31017093 Free PMC article. Clinical Trial.
-
Head-to-Head Comparison of 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer.Eur Urol Oncol. 2023 Dec;6(6):574-581. doi: 10.1016/j.euo.2023.04.006. Epub 2023 May 23. Eur Urol Oncol. 2023. PMID: 37230883
-
68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15. Eur Urol Focus. 2018. PMID: 28753806
-
Comparing the Detection Performance Between Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen PET/CT in Patients With Localized Prostate Cancer: A Systematic Review and Meta-analysis.Clin Nucl Med. 2023 Jul 1;48(7):e321-e331. doi: 10.1097/RLU.0000000000004646. Epub 2023 May 5. Clin Nucl Med. 2023. PMID: 37145456
Cited by
-
Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers (Basel). 2021 Oct 26;13(21):5360. doi: 10.3390/cancers13215360. Cancers (Basel). 2021. PMID: 34771523 Free PMC article. Review.
-
The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.Eur Urol Oncol. 2021 Jun;4(3):370-395. doi: 10.1016/j.euo.2020.11.002. Epub 2020 Dec 4. Eur Urol Oncol. 2021. PMID: 33272865 Free PMC article.
-
Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients.Diagnostics (Basel). 2021 Nov 9;11(11):2068. doi: 10.3390/diagnostics11112068. Diagnostics (Basel). 2021. PMID: 34829417 Free PMC article.
-
Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Open Sci. 2021 Sep 28;33:61-71. doi: 10.1016/j.euros.2021.09.006. eCollection 2021 Nov. Eur Urol Open Sci. 2021. PMID: 34632423 Free PMC article. Review.
-
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer.Prostate Cancer Prostatic Dis. 2025 Sep;28(3):761-766. doi: 10.1038/s41391-024-00893-1. Epub 2024 Sep 17. Prostate Cancer Prostatic Dis. 2025. PMID: 39289537
References
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J (2012) Jemal A (2015) Global cancer statistics. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262 - DOI
-
- Siegel RL, Miller KD (2016) Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332 - DOI - PubMed - PMC
-
- Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990–2007. World J Urol 26(3):211–218. https://doi.org/10.1007/s00345-008-0250-7 - DOI - PubMed - PMC
-
- D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974 - DOI
-
- Oesterling JE (1993) Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin N Am 20(4):705–711
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous